Effect of selective flora suppression on colonization, infection, and mortality in critically ill patients: a one-year, prospective consecutive study

Crit Care Med. 1991 Apr;19(4):463-73. doi: 10.1097/00003246-199104000-00003.

Abstract

Objective: To study the effect of enterally administered polymyxin E, tobramycin, and amphotericin B (selective flora suppression) on bacterial colonization, infection, resistance, and mortality rate.

Design: Prospective, consecutive crossover controlled study.

Setting: Two surgical ICUs in a university hospital; ICU I with ten beds, ICU II with eight beds.

Patients: Two hundred patients entered the 1-yr trial. Fifty of 111 patients received selective flora suppression during the first 6 months in ICU I (test group), while 61 of 111 patients served as the control group in the following 6 months. In ICU II, 49 of 89 patients received no selective flora suppression in the first 6 months (control group), followed by 40 of 89 patients receiving selective flora suppression during the second 6-month period (test group).

Interventions: The test group got a mixture of nonabsorbable antibiotics (paste and suspension) in the digestive tract. The control group received paste and suspension without antimicrobial agents. All 200 patients received cefotaxime during the first 4 days.

Measurements and main results: With the use of selective flora suppression, colonization with aerobic Gram-negative bacilli was significantly (p less than .01) reduced. There was also a significant reduction in nosocomial bronchopulmonary (ICU I and II; p less than .001) and urinary tract (ICU II; p less than .001) infections. The difference in mortality was not significant. There was no development of resistance against the antibiotics used during the limited period evaluated.

Conclusions: Selective flora suppression is effective in reducing secondary colonization by aerobic Gram-negative bacilli. Reduction of bronchopulmonary and urinary tract infections most likely occurs with colonization prevention.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Amphotericin B / administration & dosage
  • Amphotericin B / pharmacology
  • Amphotericin B / therapeutic use*
  • Bacterial Infections / microbiology
  • Bacterial Infections / mortality
  • Bacterial Infections / prevention & control*
  • Bronchopneumonia / mortality
  • Bronchopneumonia / prevention & control
  • Colistin / administration & dosage
  • Colistin / pharmacology
  • Colistin / therapeutic use*
  • Critical Care
  • Cross Infection / microbiology
  • Cross Infection / prevention & control*
  • Female
  • Gram-Negative Aerobic Bacteria / drug effects*
  • Gram-Negative Aerobic Bacteria / isolation & purification
  • Humans
  • Intensive Care Units
  • Male
  • Middle Aged
  • Mortality
  • Mouth / microbiology
  • Ointments
  • Prospective Studies
  • Sepsis / prevention & control
  • Suspensions
  • Tobramycin / administration & dosage
  • Tobramycin / pharmacology
  • Tobramycin / therapeutic use*
  • Urinary Tract Infections / prevention & control

Substances

  • Ointments
  • Suspensions
  • Amphotericin B
  • Tobramycin
  • Colistin